{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:32:54Z","timestamp":1791113574812,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1053\/j.ajkd.2008.02.297","type":"journal-article","created":{"date-parts":[[2008,4,19]],"date-time":"2008-04-19T09:08:02Z","timestamp":1208596082000},"page":"486-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial"],"prefix":"10.1053","volume":"52","clinical-trial-number":[{"clinical-trial-number":"nct00528385","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Leszek","family":"Tylicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Renke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Larczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Aleksandrowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies\u0142awa","family":"Lysiak-Szydlowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boles\u0142aw","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2008.02.297_bib1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000087842","article-title":"Renal protective effects of the renin-angiotensin-aldosterone system blockade: From evidence-based approach to perspectives","volume":"28","author":"Tylicki","year":"2005","journal-title":"Kidney Blood Press Res"},{"key":"10.1053\/j.ajkd.2008.02.297_bib2","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","volume":"99","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ajkd.2008.02.297_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","article-title":"Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial","volume":"361","author":"Nakao","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2008.02.297_bib4","first-page":"235","article-title":"Is therapy with combined ACE inhibitor and angiotensin receptor antagonist the new gold standard of treatment for nondiabetc, chronic proteinuric nephropathies?","volume":"2","author":"Ruggenenti","year":"2003","journal-title":"NephSAP"},{"key":"10.1053\/j.ajkd.2008.02.297_bib5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/j.ajkd.2003.10.032","article-title":"Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis","volume":"43","author":"Rutkowski","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2008.02.297_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-6143.2006.01588.x","article-title":"Renal allograft protection with angiotensin II type 1 receptor antagonists","volume":"7","author":"Tylicki","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2008.02.297_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2008.02.297_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0895-7061(04)00811-8","article-title":"Involvement of oxidative stress in the profibrotic action of aldosterone: Interaction with the renin-angiotension system","volume":"17","author":"Iglarz","year":"2004","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ajkd.2008.02.297_bib9","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/01.ASN.0000083982.74108.54","article-title":"Nongenomic vascular action of aldosterone in the glomerular microcirculation","volume":"14","author":"Arima","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2008.02.297_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11906-003-0087-9","article-title":"RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease","volume":"5","author":"Lakkis","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"10.1053\/j.ajkd.2008.02.297_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/ki.1985.10","article-title":"A method for estimating nitrogen intake of patients with chronic renal failure","volume":"27","author":"Maroni","year":"1985","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2008.02.297_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1053\/j.ajkd.2008.02.297_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0009-8981(76)90147-9","article-title":"Rapid calorimetric assay of \u03b2-galactosidase and N-acetyl-\u03b2-d-glucosaminidase in human urine","volume":"73","author":"Maruhn","year":"1976","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.ajkd.2008.02.297_bib14","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2008.02.297_bib15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2008.02.297_bib16","series-title":"Cross-over Trials in Clinical Research","author":"Senn","year":"2002"},{"key":"10.1053\/j.ajkd.2008.02.297_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00401706.1969.10490657","article-title":"Procedures for detecting outlying observations","volume":"11","author":"Grubbs","year":"1969","journal-title":"Technometrics"},{"key":"10.1053\/j.ajkd.2008.02.297_bib18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2008.02.297_bib19","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ajkd.2008.02.297_bib20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.amjmed.2004.04.020","article-title":"Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases","volume":"117","author":"Nitta","year":"2004","journal-title":"Am J Med"},{"key":"10.1053\/j.ajkd.2008.02.297_bib21","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1053\/j.ajkd.2005.08.034","article-title":"Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies","volume":"46","author":"Aranda","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2008.02.297_bib22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1053\/j.ajkd.2007.07.020","article-title":"Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: An 8-week uncontrolled trial","volume":"50","author":"Minutolo","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2008.02.297_bib23","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ndt\/13.7.1682","article-title":"The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide","volume":"13","author":"Butter","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2008.02.297_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.ki.5002075","article-title":"Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis","volume":"71","author":"Kramer","year":"2007","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2008.02.297_bib25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1681\/ASN.V104804","article-title":"Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein-and complement-dependent interstitial inflamation in experimental renal disease","volume":"10","author":"Abbate","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2008.02.297_bib26","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/01.TP.0000066809.60389.48","article-title":"Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients","volume":"75","author":"Teppo","year":"2003","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2008.02.297_bib27","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/ndt\/17.11.1890","article-title":"Urinary N-acetylglucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis","volume":"17","author":"Bazzi","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2008.02.297_bib28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0009-8981(00)00237-0","article-title":"Diagnostic value of urinary alanine aminopeptidase and N-acetyl-\u03b2-d-glucosaminidase in comparison to alfa-1 microglobulin as a marker in evaluating tubular dysfunction in glomerulonephritis patients","volume":"297","author":"Holdt-Lehmann","year":"2000","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.ajkd.2008.02.297_bib29","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1210\/jc.2003-030374","article-title":"Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1","volume":"88","author":"Sawathiparnich","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2008.02.297_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","article-title":"Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: Analysis of 44 cases","volume":"327","author":"Wrenger","year":"2003","journal-title":"BMJ"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638608004678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638608004678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:50:10Z","timestamp":1759456210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638608004678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0272638608004678"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2008.02.297","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2008.02.297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}